ClinicalTrials.gg
CompletedNCT02157077ARI2Updated Nov 17, 2026Results posted

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

A Phase 3 interventional study of Aflibercept in Macular Degeneration, Wet Macular Degeneration and Retinal Degeneration, sponsored by Centre Hospitalier Intercommunal Creteil. Completed at 9 sites in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionWet Macular DegenerationRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Wet Macular Degeneration
Why
  1. The study's listed conditions name Wet Macular Degeneration, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Intercommunal Creteil · Phase 3, Interventional, and Treatment

How we know

Updated Nov 17, 2026Results postedPosted results revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Wet Macular Degeneration with a site in France — 2 open to participants now, 4 under way, 3 of them phase 3. Wet Macular Degeneration · France.

Enrollment
9th of 10
84 · median 569
Started
2013
the only one that year
Phase 3
8 of 13
1 open now
Registered
1st of 13
by date
Lead sponsor
2 of 13
Centre Hospitalier Intercommunal Creteil

Among the 13 studies in Wet Macular Degeneration with a site in France, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2013, is one of 8 in phase 3, and was the 1st registered.

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

Browse Wet Macular Degeneration studies →

Open to participants now

2 of the 13 studies in Wet Macular Degeneration with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Wet Macular Degeneration with a site in France, or all of them as a file.
02

Study summary

The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.

The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.

Read the detailed description

The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.

03

Conditions studied

  • Macular Degeneration
  • Wet Macular Degeneration
  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases

Keywords

  • Eye diseases
  • Vision Impairment and Blindness
  • Eyes and Vision
  • Seniors
  • Neovascular Age-Related Macular Degeneration (AMD)
  • Retinal Disease
04

In context

Wet Macular Degeneration Reclassified

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

This study's enrollment of 84 is below the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.

Browse Wet Macular Degeneration studies →

Lead sponsor

Centre Hospitalier Intercommunal Creteil is the lead sponsor of 132 studies on the registry; 37 are open to participants now.

Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 50 years of age
  • Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD including juxtafoveal lesions that affect the fovea evidenced by Fluorescein Angiography in the study eye
  • Patient having been treated for at least 12 months with Ranibizumab (≥ 8 injections)
  • Patient with a PED > 250 µm, defined by spectral domain optical coherent tomography (SD-OCT), measured at two consecutive visits before inclusion with any persisting sub retinal fluid at baseline
  • Patient affiliated to a social security scheme
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Patient with subfoveal atrophy and/or atrophy with a diameter greater than 150µm in the subfoveal or juxtafoveal area
  • Patient with a subfoveal fibrosis
  • Subretinal hemorrhage that is either 50 percent or more of the total lesion area or 1 or more disc areas in size in the study eye.
  • Scar, fibrosis or atrophy making up > 50% of total lesion in the study eye.
  • Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
  • History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
  • Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study eye or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than AMD in either eye.
  • Any history of macular hole of stage 3 and above in the study eye.
  • Uncontrolled glaucoma (defined as intraocular pressure ≥25 mmHg despite treatment with antiglaucoma medication) or prior laser treatment for glaucoma in the study eye.
  • Active intraocular inflammation or uveitis of scleritis or episcleritis in the study eye or ocular or periocular infection in either eye
  • Presence or history of scleromalacia in the study eye.
  • Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye.
  • Previous therapeutic radiation in the study eye.
  • History of corneal transplant or corneal dystrophy in the study eye.
  • Significant media opacities, including cataract, in the study eye which might interfere with visual acuity, assessment of toxicity, or fundus photography.
  • Any concurrent intraocular condition in the study eye (e.g. cataract) that, in the opinion of the investigator, could require either medical or surgical intervention during the 24 month study period.
  • Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.
  • Any systemic treatment with an agent except dietary supplements or vitamins in the past 6 months prior to Day 1 for any condition.
  • Any history of allergy to povidone iodine.
  • as listed
  • Patient enrolled in another interventional research or not
  • Patient already included in the study for the treatment of one of his eye
  • Pregnant or nursing woman
  • Lack of effective for women of childbearing age
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Aflibercept

    Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26

    Drug: Aflibercept

Interventions

  • Intravitreal Injection

    Also known as: Eylea, BAY86-5321

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Maximal Height of Pigment Epithelium Detachment (PED) at 12 Weeks

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change From Baseline in Central Retinal Thickness by SD OCT at 12 Weeks

    Time frame: Baseline and 12 weeks

  2. Best-corrected Visual Acuity at 12 Weeks

    Best-corrected visual acuity (BCVA) was measured using ETDRS letter scores.

    Time frame: 12 weeks

  3. Pigment Epithelial Detachment Volume at 12 Weeks

    Pigment epithelial detachment volume was assessed by SD-OCT and semiautomated volumetric analysis.

    Time frame: 12 weeks

  4. Central Retinal Thickness at 32 Weeks

    Time frame: 32 weeks

  5. Pigment Epithelium Detachment Height at 32 Weeks

    Time frame: 32 weeks

  6. Visual Acuity at 32 Weeks

    Time frame: 32 weeks

  7. Volume of Pigment Epithelium Detachment at 32 Weeks

    Time frame: 32 weeks

  8. Pigment Epithelium Detachment Height at 12 Weeks

    Maximal pigment epithelial detachment (PED) height was assessed by spectral-domain optical coherence tomography (SD-OCT).

    Time frame: Week 12

08

Results

Posted Oct 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneAflibercept
Started84
Completed83
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryChange From Baseline in Maximal Height of Pigment Epithelium Detachment (PED) at 12 Weeks
Time frame:
Baseline and 12 weeks
Reported as:
Mean · micrometers
Change From Baseline in Maximal Height of Pigment Epithelium Detachment (PED) at 12 Weeks
micrometersAflibercept
Change From Baseline in Maximal Height of Pigment Epithelium Detachment (PED) at 12 Weeks-81.29 (-101.3 to -61.3)
Statistical analysis
  • Aflibercept · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Central Retinal Thickness by SD OCT at 12 Weeks
Time frame:
Baseline and 12 weeks
Reported as:
Mean · micrometers
Change From Baseline in Central Retinal Thickness by SD OCT at 12 Weeks
micrometersAflibercept
Change From Baseline in Central Retinal Thickness by SD OCT at 12 Weeks-65.82 ± 159.86
Statistical analysis
  • Aflibercept · t-test, 2 sided · p = <0.001
SecondaryBest-corrected Visual Acuity at 12 Weeks

Best-corrected visual acuity (BCVA) was measured using ETDRS letter scores.

Time frame:
12 weeks
Reported as:
Mean · ETDRS letters
Best-corrected Visual Acuity at 12 Weeks
ETDRS lettersAflibercept
Best-corrected Visual Acuity at 12 Weeks68.4 ± 14.8
Statistical analysis
  • Aflibercept · t-test, 2 sided · p = 0.055
SecondaryPigment Epithelial Detachment Volume at 12 Weeks

Pigment epithelial detachment volume was assessed by SD-OCT and semiautomated volumetric analysis.

Time frame:
12 weeks
Reported as:
Mean · mm^3
Pigment Epithelial Detachment Volume at 12 Weeks
mm^3Aflibercept
Pigment Epithelial Detachment Volume at 12 Weeks0.95 ± 0.85
SecondaryCentral Retinal Thickness at 32 Weeks
Time frame:
32 weeks
Reported as:
Mean · micrometers
Central Retinal Thickness at 32 Weeks
micrometersAflibercept
Central Retinal Thickness at 32 Weeks387.42 ± 161.34
SecondaryPigment Epithelium Detachment Height at 32 Weeks
Time frame:
32 weeks
Reported as:
Mean · micrometers
Pigment Epithelium Detachment Height at 32 Weeks
micrometersAflibercept
Pigment Epithelium Detachment Height at 32 Weeks288.22 ± 123.53
SecondaryVisual Acuity at 32 Weeks
Time frame:
32 weeks
Reported as:
Mean · ETDRS letters
Visual Acuity at 32 Weeks
ETDRS lettersAflibercept
Visual Acuity at 32 Weeks69.5 ± 14
SecondaryVolume of Pigment Epithelium Detachment at 32 Weeks
Time frame:
32 weeks
Reported as:
Mean · mm^3
Volume of Pigment Epithelium Detachment at 32 Weeks
mm^3Aflibercept
Volume of Pigment Epithelium Detachment at 32 Weeks1 ± 0.87
SecondaryPigment Epithelium Detachment Height at 12 Weeks

Maximal pigment epithelial detachment (PED) height was assessed by spectral-domain optical coherence tomography (SD-OCT).

Time frame:
Week 12
Reported as:
Mean · micrometers
Pigment Epithelium Detachment Height at 12 Weeks
micrometersAflibercept
Pigment Epithelium Detachment Height at 12 Weeks266.04 ± 114.56

Adverse events

Collected over Baseline to Week 32. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept0/84 (0%)4/84 (4.8%)0/84 (0%)
Most frequent serious events
Most frequent serious events
EventAflibercept
Cardiovascular disordersCardiac disorders3/84
Confused stateEye disorders1/84
Most frequent other events
Most frequent other events
EventAflibercept
Other serious adverse eventsEye disorders0/84

Baseline characteristics

Baseline characteristics were analyzed in the intention-to-treat population, including all 84 enrolled participants who completed at least one follow-up visit after enrollment.

Age, Categorical
Age, Categorical(Participants)Aflibercept
<=18 years0
Between 18 and 65 years1
>=65 years83
Age, Continuous
Age, Continuous(years)Aflibercept
Mean80.5 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept
Female59
Male25
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Aflibercept
Region of Enrollment
Region of Enrollment(Participants)Aflibercept
France84
09

Study locations

9 sites
  • Hôpital Pellegrin
    Bordeaux, 33000, France
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, 94010, France
  • Hôpital général de Dijon
    Dijon, 21033, France
  • Centre d'Ophtalmologie Rabelais
    Lyon, 69003, France
  • Cabinet Alpes Rétine
    Montbonnot-Saint-Martin, 38330, France
  • CHR Hôtel Dieu
    Nantes, 44093, France
  • Centre d'explorations ophtalmologiques de l'odéon
    Paris, 75006, France
  • Hôpital des Quinze-Vingts
    Paris, 75012, France
  • Clinique Mathilde
    Rouen, 76100, France
10

References and documents

Publications

  • Mouallem-Beziere A, Blanco-Garavito R, Richard F, Miere A, Jung C, Rozet JM, Souied EH. GENETICS OF LARGE PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2020 Apr;40(4):663-671. doi: 10.1097/IAE.0000000000002454. PubMed 30681643 ↗
11

Timeline

3 registry updates since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2026, 10 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2014
First posted
Jun 5, 2014
Start
Dec 2013
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Oct 5, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 5, 2026 · revised Oct 27, 2026 · revised Nov 17, 2026
Enrollment
90→84
Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in maximal heightMaximal Height of pigment epithelium detachmentPigment Epithelium Detachment (PED) at 12 weeksWeeksTime frame: Baseline and 12 weeks
Oct 5, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 5, 2026
  • EditedChange from baselineFrom Baseline in central retinal thicknessCentral Retinal Thickness by SD OCT at 12 weeksWeeksTime frame: Baseline and 12 weeks
  • EditedChange from Baseline in visual acuityBest-corrected Visual Acuity at 12 weeksWeeksTime frame: Baseline and 12 weeks → 12 weeks
  • EditedChange from Baseline in volume of pigment epithelium detachmentPigment Epithelium Detachment Height at 12 weeks32 WeeksTime frame: Baseline and 12 weeks → 32 weeks
  • EditedChange from Baseline in pigment epithelium detachment heightPigment Epithelial Detachment Volume at 12 weeksWeeksTime frame: Baseline and 12 weeks → 12 weeks
  • EditedChange from baseline in central retinal thicknessCentral Retinal Thickness at 32 weeksWeeksTime frame: baseline and 32 weeks → 32 weeks
  • EditedChange from Baseline in pigment epithelium detachment heightVolume of Pigment Epithelium Detachment at 32 weeksWeeksTime frame: Baseline and 32 weeks → 32 weeks
  • EditedChange from Baseline in visual acuityVisual Acuity at 32 weeksWeeksTime frame: Baseline and 32 weeks → 32 weeks
  • RemovedAssociation with genes involved in AMD historyTime frame: genetic testing will be performed when all the particpitants will be recruited
  • RemovedNumber of participants with adverse events from baseline to 32 weeksTime frame: from baseline to 32 weeks
  • RemovedChange from Baseline in volume of pigment epithelium detachment at 32 weeksTime frame: Baseline and 32 weeks
What changed on Oct 27, 2026
  • AddedPigment Epithelium Detachment Height at 12 WeeksTime frame: Week 12
across 2 updates, Oct 5, 2026 – Oct 27, 2026
Show all 3 updates
  1. Nov 17, 2026
    Posted results revised
  2. Oct 27, 2026
    Posted results revised
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedPigment Epithelium Detachment Height at 12 WeeksTime frame: Week 12
    + 1 other change: verification date
  3. Oct 5, 2026
    Results posted
    Enrollment 90→84
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in maximal heightMaximal Height of pigment epithelium detachmentPigment Epithelium Detachment (PED) at 12 weeksWeeksTime frame: Baseline and 12 weeks
    Secondary outcomes 7 edited, 3 removed
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in central retinal thicknessCentral Retinal Thickness by SD OCT at 12 weeksWeeksTime frame: Baseline and 12 weeks
    • EditedChange from Baseline in visual acuityBest-corrected Visual Acuity at 12 weeksWeeksTime frame: Baseline and 12 weeks → 12 weeks
    • EditedChange from Baseline in volume of pigment epithelium detachmentPigment Epithelium Detachment Height at 12 weeks32 WeeksTime frame: Baseline and 12 weeks → 32 weeks
    • EditedChange from Baseline in pigment epithelium detachment heightPigment Epithelial Detachment Volume at 12 weeksWeeksTime frame: Baseline and 12 weeks → 12 weeks
    • EditedChange from baseline in central retinal thicknessCentral Retinal Thickness at 32 weeksWeeksTime frame: baseline and 32 weeks → 32 weeks
    • EditedChange from Baseline in pigment epithelium detachment heightVolume of Pigment Epithelium Detachment at 32 weeksWeeksTime frame: Baseline and 32 weeks → 32 weeks
    • EditedChange from Baseline in visual acuityVisual Acuity at 32 weeksWeeksTime frame: Baseline and 32 weeks → 32 weeks
    • RemovedAssociation with genes involved in AMD historyTime frame: genetic testing will be performed when all the particpitants will be recruited
    • RemovedNumber of participants with adverse events from baseline to 32 weeksTime frame: from baseline to 32 weeks
    • RemovedChange from Baseline in volume of pigment epithelium detachment at 32 weeksTime frame: Baseline and 32 weeks
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT02157077
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jun 5, 2014
Start date
Dec 2013
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Oct 5, 2026
Last update
Nov 17, 2026

Study contacts

Eric Souied, MD
study director · Centre Hospitalier Intersommunal de Créteil

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion